Design, synthesis and biological evaluation of a novel PSMA–PI3K small molecule drug conjugate-Reference-Cited by-同舟云学术

Design, synthesis and biological evaluation of a novel PSMA–PI3K small molecule drug conjugate

Published:2024 Issue: Volume: Page:
ISSN:2632-8682
Container-title:RSC Medicinal Chemistry
language:en
Short-container-title:RSC Med. Chem.

Author:

Peng Shouguo¹²³,Li Haixia⁴,Cui Weilu⁴,Xiong Tianning¹²³,Hu Jiaqi¹²³,Qi Haixiang¹²³,Lin Songwen¹²³,Wu Deyu¹²³,Ji Ming¹³,Xu Heng¹²³^ORCID

Affiliation:

1. State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China

2. Beijing Key Laboratory of Active Substances Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China

3. CAMS Key Laboratory of Small Molecule Immuno-Oncology Drug Discovery, Chinese Academy of Medical Sciences, Beijing, 100050, China

4. Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China

Abstract

A novel PSMA–PI3K small molecule drug conjugate has been prepared, highlighting its potential in targeted cancer therapy.

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/MD/D4MD00246F

Reference32 articles.

1. Small molecule drug conjugates (SMDCs): an emerging strategy for anticancer drug design and discovery

2. Small molecule-drug conjugates: A novel strategy for cancer-targeted treatment

3. Ligand-Targeted Drug Delivery

4. Enhancing the Safety and Efficacy of PSMA-Based Small-Molecule Drug Conjugates by Linker Stabilization and Conjugation to Transthyretin Binding Ligand

5. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism